BACKGROUND: Cardiac cell transplantation is limited by poor graft viability. We aimed to enhance the survival of transplanted cardiomyoblasts using growth factor-supplemented collagen matrices. METHODS AND RESULTS: H9c2 cardiomyoblasts were lentivirally transduced to express firefly luciferase and green fluorescent protein (GFP). Lewis rats underwent ligation of the left anterior descending artery (LAD) ligation to induce an anterior wall myocardial infarction. Hearts (n=9/group) were harvested and restored ex vivo with 1 x 10(6) genetically labeled H9c2 cells either in (1) saline-suspension, or seeded onto (2) collagen-matrix (Gelfoam [GF];), (3) GF/Matrigel (GF/MG), (4) GF/MG/VEGF (10 microg/mL), or (5) GF/MG/FGF (10 microg/mL). Hearts were then abdominally transplanted into syngeneic recipients (working heart model). Controls (n=6/group) underwent infarction followed by GF implantation or saline injection. Cell survival was evaluated using optical bioluminescence on days 1, 5, 8, 14, and 28 postoperatively. At 4 weeks, fractional shortening and ejection fraction were determined using echocardiography and magnetic resonance imaging, respectively. Graft characteristics were assessed by immunohistology. Bioluminescence signals on days 5, 8, and 14 were higher for GF-based grafts compared with plain H9c2 injections (P<0.03). Signals were higher for GF/MG grafts compared with GF alone (P<0.02). GFP-positive, spindle-shaped H9c2 cells were found integrated in the infarct border zones at day 28. Left ventricular (LV) function of hearts implanted with collagen-based grafts was better compared with controls (P<0.05). Vascular endothelial growth factor or fibroblast growth factor did not further improve graft survival or heart function. CONCLUSIONS: Collagen matrices enhance early survival of H9c2 cardiomyoblasts after transplantation into ischemic hearts and lead to improved LV function. Further optimization of the graft design should make restoration of large myocardial infarctions by tissue engineering approaches effective.
BACKGROUND: Cardiac cell transplantation is limited by poor graft viability. We aimed to enhance the survival of transplanted cardiomyoblasts using growth factor-supplemented collagen matrices. METHODS AND RESULTS:H9c2 cardiomyoblasts were lentivirally transduced to express firefly luciferase and green fluorescent protein (GFP). Lewis rats underwent ligation of the left anterior descending artery (LAD) ligation to induce an anterior wall myocardial infarction. Hearts (n=9/group) were harvested and restored ex vivo with 1 x 10(6) genetically labeled H9c2 cells either in (1) saline-suspension, or seeded onto (2) collagen-matrix (Gelfoam [GF];), (3) GF/Matrigel (GF/MG), (4) GF/MG/VEGF (10 microg/mL), or (5) GF/MG/FGF (10 microg/mL). Hearts were then abdominally transplanted into syngeneic recipients (working heart model). Controls (n=6/group) underwent infarction followed by GF implantation or saline injection. Cell survival was evaluated using optical bioluminescence on days 1, 5, 8, 14, and 28 postoperatively. At 4 weeks, fractional shortening and ejection fraction were determined using echocardiography and magnetic resonance imaging, respectively. Graft characteristics were assessed by immunohistology. Bioluminescence signals on days 5, 8, and 14 were higher for GF-based grafts compared with plain H9c2 injections (P<0.03). Signals were higher for GF/MG grafts compared with GF alone (P<0.02). GFP-positive, spindle-shaped H9c2 cells were found integrated in the infarct border zones at day 28. Left ventricular (LV) function of hearts implanted with collagen-based grafts was better compared with controls (P<0.05). Vascular endothelial growth factor or fibroblast growth factor did not further improve graft survival or heart function. CONCLUSIONS: Collagen matrices enhance early survival of H9c2 cardiomyoblasts after transplantation into ischemic hearts and lead to improved LV function. Further optimization of the graft design should make restoration of large myocardial infarctions by tissue engineering approaches effective.
Authors: D Ladage; I C Turnbull; K Ishikawa; Y Takewa; K Rapti; C Morel; I Karakikes; L Hadri; J Müller-Ehmsen; K D Costa; R J Hajjar; Y Kawase Journal: Gene Ther Date: 2011-04-21 Impact factor: 5.250
Authors: Kristine C Rustad; Victor W Wong; Michael Sorkin; Jason P Glotzbach; Melanie R Major; Jayakumar Rajadas; Michael T Longaker; Geoffrey C Gurtner Journal: Biomaterials Date: 2011-10-02 Impact factor: 12.479
Authors: Andrew S Lee; Mohammed Inayathullah; Maarten A Lijkwan; Xin Zhao; Wenchao Sun; Sujin Park; Wan Xing Hong; Mansi B Parekh; Andrey V Malkovskiy; Edward Lau; Xulei Qin; Venkata Raveendra Pothineni; Verónica Sanchez-Freire; Wendy Y Zhang; Nigel G Kooreman; Antje D Ebert; Charles K F Chan; Patricia K Nguyen; Jayakumar Rajadas; Joseph C Wu Journal: Nat Biomed Eng Date: 2018-02-06 Impact factor: 25.671
Authors: Xintong Wang; Young Wook Chun; Lin Zhong; Manuel Chiusa; Daniel A Balikov; Audrey Y Frist; Chee C Lim; Simon Maltais; Leon Bellan; Charles C Hong; Hak-Joon Sung Journal: Int J Cardiol Date: 2015-04-18 Impact factor: 4.164
Authors: Kristin M French; Archana V Boopathy; Jessica A DeQuach; Loice Chingozha; Hang Lu; Karen L Christman; Michael E Davis Journal: Acta Biomater Date: 2012-07-27 Impact factor: 8.947